Addressing the selectivity and toxicity of antiviral nucleosides

Joy Y Feng

Abstract
Nucleoside and nucleotide analogs have played significant roles in antiviral therapies and are valued for their impressive potency and high barrier to resistance. They have been approved for treatment of herpes simplex virus-1, HIV, HBV, HCV, and influenza, and new drugs are being developed for the treatment of RSV, Ebola, coronavirus MERS, and other emerging viruses. However, this class of compounds has also experienced a high attrition rate in clinical trials due to toxicity. In this review, we discuss the utility of different biochemical and cell-based assays and provide recommendations for assessing toxicity liability before entering animal toxicity studies.

Keywords
Nucleosides, nucleotides, prodrugs, antiviral therapy, virus, polymerase, chain termination, selectivity

Date received: 17 October 2017; accepted: 10 January 2018

Nucleoside analogs were first studied as antimetabolites in the 1950s by George Hitchings and Gertrude Elion.1 Their work led to the discovery of treatments for leukemia, gout, hyperuricemia, and parasitic protozoan infection, as well as an immunosuppressant for organ transplant. These efforts paved the way for the discovery of a series of nucleoside analogs as antitumor agents in the 1970s, some of which, such as ara-C and gemcitabine (Figure 1), are still in use today.2,3 Many of these antitumor nucleoside analogs showed antiviral activity, but none of them possessed an adequate clinical safety profile for antiviral use until Acyclovir (Figure 1) was discovered for the treatment of herpes simplex virus (HSV) infection, a breakthrough that started a new era in antiviral therapy.1 Acyclovir’s remarkable safety profile stemmed from two properties: (1) activation of the compound to its monophosphate (MP) only occurs in virus-infected cells, since this process relies on a viral thymidine kinase; and (2) acyclovir 5’-triphosphate (TP) selectively inhibits viral DNA polymerase over host DNA polymerase α.4 Follow on generations of HSV nucleoside antivirals (penciclovir and ganciclovir, Figure 1) and prodrugs were developed to improve potency and resistance profiles.5

The HIV/AIDS epidemic in the 1980s presented unprecedented demand for effective antivirals. In 1986, azidothymidine (AZT, zidovudine, Figure 1), a chain-terminating inhibitor of HIV-1 reverse transcriptase (RT), was approved, signifying the first step towards control of this devastating disease. The first generation of nucleoside analogs for HIV was efficacious, but these compounds also showed considerable toxicity, including cardiomyopathy (AZT, ddI, and ddC, Figure 1), peripheral neuropathy (d4T, ddI, and ddC), sensorineural deafness (ddC), lactic acidosis (AZT, ddI, and d4T), diabetes (ddI), and cytopenia (AZT).6,7 The toxicity of ddC and AZT was associated with inhibition of mitochondria DNA synthesis in cell culture8–10 and in patient tissue samples.11 Later on, detailed kinetic studies of HIV nucleosides using recombinant human mitochondrial DNA polymerase (Pol γ) demonstrated the importance of selective inhibition of on-target HIV-1 RT over that of the off-target human Pol γ.12 Unfortunately, this knowledge came 10 years too late to inform the 1993 Phase II clinical trial of FIAU in patients infected with HBV, where 7 out of 15 patients developed severe liver toxicity and
lactic acidosis, and 5 of these patients died.\textsuperscript{13} Follow-up biochemical, cellular, and in vivo studies showed that FIAU was readily incorporated into mitochondrial DNA, leading to a decrease in mtDNA abundance and thus rendering the mitochondria dysfunctional.\textsuperscript{14,15} The prevalence of mitochondrial toxicity associated with 2'-deoxy nucleoside analogs led to the FDA's recommendation to test drug candidates in a set of mitochondrial toxicity assays including Pol $\gamma$ inhibition, lactic acid formation, mitochondrial DNA content, and glucose utilization.\textsuperscript{16} With the use of these tests, the second-generation antiviral nucleoside/tide analogs such as 3TC, FTC, and tenofovir were shown to be poor substrates of Pol $\gamma$ and demonstrated significantly improved clinical safety profiles.

Despite our collective knowledge of nucleoside analog-associated mitochondrial toxicity, safety concerns continued in the discovery of HCV antivirals. A number of HCV nucleoside/tide analogs failed in Phase II due to toxicity or association with a toxic analog. These include valopicitabine (NM283, gastrointestinal toxicity, Figure 1),\textsuperscript{17} balapiravir (R1626, hematologic toxicity, Figure 1),\textsuperscript{17} BMS-986094 (cardiac and kidney toxicity, Figure 1),\textsuperscript{18} IDX184 (clinical hold due to association with

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{chemical_structures.png}
\caption{Chemical structures of compounds discussed in this review.}
\end{figure}
BMS-986094, Figure 1),\textsuperscript{19} and PSI-938 (liver toxicity, Figure 1).\textsuperscript{17} With the exception of PSI-938, the TP forms of these compounds are substrates of mitochondrial RNA polymerase (POLRMT). Balapiravir is a specific mitochondria toxin, inhibits POLRMT, reduces mitochondrial protein synthesis, and eventually decreases mitochondrial respiration.\textsuperscript{20,22} Furthermore, Jin et al. demonstrated that the toxicity of BMS-986094 is directly correlated to its 2'CMeGMP nucleotide moiety rather than the naphthalene-phosphorylamino propanoate prodrug moiety.\textsuperscript{21} Interestingly, when compared to selective mitochondria inhibitors such as ddC, 4-azidoC, and chloramphenicol (Figure 1), the inhibition profile of BMS-986094 is distinctly different for mitochondrial protein synthesis and respiration, indicating it may hit other off-targets such as RNA polymerase I.\textsuperscript{20} As of today, the only approved nucleotide prodrug for the treatment of HCV is sofosbuvir (Figure 1), a 2'F, 2'CMe uridine prodrug that is well tolerated in patients.\textsuperscript{23} The TP form of sofosbuvir showed no inhibition of any of the human polymerases tested and is a poor substrate of POLRMT.\textsuperscript{20} The relevance of POLRMT inhibition as a marker for nucleotide toxicity has been further supported by works from multiple groups.\textsuperscript{20,21,22,24} A clear outlier is PSI-938, a 2'F, 2'CMe guanosine prodrug, which showed liver toxicity in clinical trials but is a poor substrate of POLMRT and showed no toxicity in any of the in vitro studies conducted so far.\textsuperscript{20}

Host polymerases have been generally regarded as the primary off-targets for this class of compounds. However, the observed toxicities tend to be highly unpredictable.\textsuperscript{7,25} These may be attributed to complex uptake, distribution, and accumulation of different compound in different organs. For example, three closely related analogs, FIAU, FMAU, and FIAC (Figure 1), showed distinctly different toxicities in animals and human. FIAU showed no toxicity in nonclinical animal species including mice, rats, dogs, and monkeys, but conflicting toxicity findings from two separate studies in woodchucks.\textsuperscript{15,26} In contrast, FIAU-induced hepatotoxicity was observed in clinical trials in week 13 and beyond under potentially much lower exposures than the animal models.\textsuperscript{15,26} In addition, FMAU, a metabolite of FIAU, was tested in a Phase I clinical trial for the treatment of murine leukemia. It caused severe neurologic toxicity and two deaths among eight patients after 8–10 days of treatment. Toxicity, primarily hematopoietic, was observed with FIAC, the cytidine analog and known metabolic precursor of FIAU, when used to treat HSV and vesicular stomatitis virus infection.\textsuperscript{26} Interestingly, while the more recent HCV nucleotide antivirals, e.g. BMS-986094, PSI-938, and VX-135 (also known as ALS-2200, Figure 1) were all liver-targeting nucleotide prodrugs and the administration of PSI-938 and VX-135 resulted in liver toxicity,\textsuperscript{27,28} BMS-986094 showed cardiovascular and renal toxicity.\textsuperscript{29}

It is worthwhile mentioning that antiviral nucleosides could also exert toxicity through disruption of natural NTP pools. AZT only showed modest inhibition of mitochondrial DNA polymerase\textsuperscript{7} but is a competitive inhibitor of thymidine kinase 2-catalized phosphorylation of thymidine to TMP.\textsuperscript{30} Ribavirin is a poor substrate for mitochondrial RNA polymerase,\textsuperscript{22} but it reduces the size of the guanosine triphosphate (GTP) pool via inhibition of inosine MP dehydrogenase.\textsuperscript{31}

As one might expect, there are many possible ways that a nucleoside/tide analog can elicit toxicity that are still beyond our knowledge. In this review, we focus on the host polymerase mechanism-based toxicity and summarize different biochemical and cellular assays to evaluate potential toxicity liabilities, and the strength and limitations of each method.

**Biochemical evaluations**

As most nucleoside/tides analogs need to be transformed into 5'-TP to exert on-target and off-target effects, their TP forms are necessary for elucidating these mechanisms (Table 1). The typical initial enzymatic assay for polymerases is a radioactivity-based polymerization assay, in which the inhibition by nucleotides is measured as an IC\textsubscript{50} value. The inhibition IC\textsubscript{50} assays can be easily adapted to a 96-well filter binding assay, and multiple compounds can be accessed simultaneously. However, based on inhibition studies alone, one cannot establish whether the nucleotide was actually incorporated. Therefore, a single nucleotide incorporation (SNI) assay can be particularly useful to determine if a NTP analog actually served as a substrate for the polymerases. Under a high concentration of NTP analogs (e.g. 500 μM ribose nucleotide TP (rNTP) or 50–100 μM 2'-deoxyribose nucleotide TP (dNTP)), the relative rate of incorporation of an analog can be compared to that of its natural NTP counterpart. For further mechanistic insight, a pre-steady state kinetic analysis of the NTP incorporation offers detailed kinetic parameters such as pre-steady state polymerization rate constant k\textsubscript{pol} and NTP dissociation constant K\textsubscript{d}. In these studies, incorporation rates are studied using multiple time points and nucleotide concentrations, often using quench-flow techniques, making these studies reagent- and time-consuming. Finally, the mechanism of a
nucleotide analog-derived enzyme inhibition can be revealed by an elongation assay, in which a stable elongation complex is formed, and the incorporation of the next few natural NTPs is measured. Normally, an NTP analog can be characterized into one of the three groups: chain-terminators, delayed chain-terminators, or stably incorporated analogs. Stably incorporated NTP analogs are difficult to study for toxicity as they could lead to little or no quantitative changes in DNA, RNA, or protein expression.36

The quality of the above-mentioned biochemical assays relies heavily on the availability of high quality TP active forms, which can be time- and resource-consuming to synthesize, and the TP salts are subject to degradation overtime. At times, certain inorganic contaminants could lead to apparent inhibition of polymerases.

### Table 1. Biochemical and cellular assays to evaluate general and mitochondria toxicities of nucleoside/tide analogs.

| Types of assays | Assay | Assay design and references | Platform |
|----------------|-------|----------------------------|----------|
| Biochemical    | IC₅₀ and Kᵢ | Inhibition of a host polymerase for DNA or RNA synthesis.32,33 The concentrations of natural dNTP or NTP are set near their corresponding Kᵢₜ₉₀. | Radiometric filter-binding |
| SNI            | Incorporation of a single NTP analog by host polymerases using a set of primer/template with defined sequence at a high concentration of NTP analogs.32,33 | Radiometric PAGE |
| Elongation     | Further incorporation of natural NTPs after incorporation of a NTP analog.20,22 Used to determine if a NTP analog caused chain termination. | Radiometric PAGE |
| Pre-steady state | Detailed kinetic studies for the incorporation of a NTP analog to measure the rate constant of incorporation kₚₒˡ (s⁻¹) and binding affinity Kᵢ (μM).7 | Radiometric PAGE |
| Cellular       | Viability | After 5–10 day compound treatment, cell viability is measured by ATP level (CellTiterGlo), mitochondrial health (MTT/XTT), or other indicators.34 | Plate reader |
| Mitochondrial DNA content | After 14-day compound treatment in HepG2 cells, levels of the mitochondria-encoded cytochrome b gene are normalized to the levels of nuclear-encoded DNA β-actin gene.35 | PCR |
| Mitochondria protein synthesis | After 5-day compound treatment in PC-3 cells, levels of mitochondria DNA-encoded protein COX-I and nuclear DNA-encoded protein SDH-A are measured.32 | In-Cell ELISA |
| Cellular respiration | After 3-day compound treatment in PC-3 cells, cells are subjected to a Mito Stress Test and the mitochondrial spare respiration capacity was measured.20 | Seahorse™ XFe96 Cellular Flux |

SNI: single nucleotide incorporation; NTP: nucleotide triphosphate; PAGE: polyacrylamide gel electrophoresis; PCR: polymerase chain reaction.

### Cellular evaluations

**Toxicity is cell line-dependent**

Due to their mechanism of action, nucleoside analogs are generally evaluated for 5–8 days in both replicating laboratory-adapted cell lines and non-replicating primary cells.18 A standard readout is the effect of compound on the ATP level within the cells. We found that among 20+ laboratory-adapted cells we tested, prostate cancer-derived PC-3 cells and T-cell leukemia-derived MT4 cells are generally the most sensitive to toxins, and are significantly more sensitive than HepG2 cells, a widely used cell line for in vitro toxicity studies. In addition, we found that laboratory-adapted cells are as useful for detecting potential toxicity liabilities as primary cells.

In certain cases, testing in a specific cell assay is warranted. For example, a number of the...
first-generation HIV nucleoside analogs showed myelo-
suppressive effects. As a result, the FDA recommended
evaluating this toxicity on the growth of human bone
marrow progenitor cells in colony forma-
tion assays.37

The importance of measuring cellular TP levels
A nucleoside/tide analog’s cytotoxicity is often directly
related to its cellular level of the active TP metabolite.
BMS-986094 and IDX184 are both 2’CMe guanosine
nucleotide prodrugs, but the former formed >37-fold
higher TP, and this correlated with its significantly
higher toxicity.18 Some nucleoside analogs are poorly
phosphorylated in cells, such as balapiravir. Even
though it is a specific inhibitor of POLRMT, balapir-
avir showed little or no toxicity in a large panel of cell
lines and primary cells tested, but development of this
compound was stopped at Phase II due to toxicity.

Evaluation of mitochondrial toxicity
As shown in Table 1, we employed three mitochondria-
focused cell-based assays to evaluate potential mito-
chondrial toxicity. The mitochondrial DNA content
assay has been widely used to study 2’-deoxy nucleoside
analogs, but it does not assess the effect of ribose nucle-
osome/tide analogs on mitochondrial RNA synthesis.20,29
dDC serves as a good positive control and HepG2 cells seem to be an ideal cell line for this assay.
The mitochondrial protein synthesis assay has been
useful to evaluate ribonucleoside/tide analogs. In this
assay, the levels of two proteins are measured simulta-
aneously: the mitochondrial DNA-encoded protein
cytochrome c oxidase 1 (COX-1) and a nuclear
DNA-encoded protein succinate dehydrogenase A
(SDH-A).32 For data analysis, we found that compar-
ing the individual levels of the COX-1 and SDH-A
proteins to the untreated DMSO control yielded
more reproducible data than using the ratio of COX-
1:SDH-A. Chloramphenicol, a specific inhibitor of
mitochondrial protein synthesis, is used as the positive
control.

Since the 1950s, mitochondrial respiration has been
regarded as the “gold standard” for the measurement
of mitochondrial function.38 It has been used extensive-
ly to study mitochondrial toxins that directly impair
the electron transport chain but has not been used to
study the nucleoside/tide analogs until recently.39–42
This assay provides a sensitive functional readout and
does not require knowledge of the mechanism of action.20
A complete loss of mitochondrial respiration
capacity can be detected before any change in the cel-
ular ATP level, and this phenomenon has been
observed for inhibitors with diverse molecular targets
including ddC (inhibitor of mitochondrial DNA syn-
thesis), 4’-azido cytidine (inhibitor of mitochondrial
RNA synthesis), and chloramphenicol (inhibitor of
mitochondrial protein synthesis). For compounds that
show both mitochondrial and general toxicity (such as
BMS-986094), this method makes it possible to identify
whether mitochondria toxicity occurs at a lower drug
dose.20 For both mitochondrial protein and respiration
assays, we found that PC-3 cells offer higher sensitivity and reproducibility than HepG2
cells.20

An assay with limited predictive value: The
glucose–galactose CC50 assay
When faced with mitochondria damage, cells are
known to switch to glycolysis to generate ATP; there-
fore the glucose–galactose CC50 assay has been widely
used to detect mitochondria toxicity.43 In the absence
of glucose, the galactose-adapted cells are forced to rely
heavily on mitochondrial OXPHOS and thus would
show a ≥3-fold decrease in CC50.44 However, the predict-
vity of this assay was challenged by Hyne’s 2013
report showing that this assay only detected 2–5% of
the 200 potential mitochondrial toxins tested.44,45 Even
though no nucleoside/tide analogs were included in
Hyne’s study, it is consistent with our finding from
testing >30 clinically relevant nucleoside/tide analogs.
None of the known mitochondrial toxins such as ddC,
FIAU, or 4’-azido C showed enhanced cytotoxicity in
galactose-adapted cells.

Evaluation of toxicity in animal studies
Research and development of a significant number of
nucleoside/tide analogs were terminated in the pre-
clinical stage due to toxicity in the animal models;
though only a few were reported24,46,47 and mitochon-
drial toxicity was indicated or suspected. To date, due
to a number of factors outlined above, mitochondrial
toxicity has been difficult to detect in animal species
and correlation to humans is at best tenuous.48
Potentially, animal models with genetic mitochondrial
abnormalities or humanized animals may be more sen-
sitive to nucleoside/tide toxicity. For example, mice
models with genetic mitochondrial abnormalities such
as heterozygous superoxide dismutase 2 knockout
(Sod1/−) mice were more susceptible to mitochondria
toxins than the wild-type animals.49 Recently, Xu et al.
reported FIAU-induced liver toxicity in chimeric TK-
NOG mice grafted with humanized livers.50 Animal
models like these may improve our ability to detect
nucleoside toxicity.
A comment on therapeutic window

As viral diseases vary greatly in duration and severity, the safety threshold of an antiviral nucleoside/tide needs to be considered in the context of its efficacy and treatment duration. For example, compounds to treat acute and deadly viral infections such as Ebola would likely have different safety criteria than drugs used to control chronic infections such as HIV-1 and HBV. Existing nucleoside/tides are routinely screened against emerging viruses, and it is possible that a compound that failed to achieve an adequate therapeutic window against one virus may be suitable for treating other viral infections.

Summary

Anti-viral nucleoside/tide analogs target the viral DNA and RNA replication machinery, and this mechanism makes them potential inhibitors of host DNA and RNA synthesis as well, especially mitochondrial DNA and RNA synthesis. Mitochondrial toxicity manifests in multiple forms in vivo and underlies many clinical-stage failures and has been difficult to detect in animal studies. Over the past 30 years, a battery of in vitro tests for mitochondrial toxicity has evolved and continues to expand, allowing for improved early detection of mitochondrial liability. As for any drug molecule, the actual toxicity liability cannot be assessed fully until tested in animal toxicity studies and eventually in human clinical trials. Nevertheless, we believe that employing the proper biochemical and cellular assays early on will have a meaningful impact on reducing pre-clinical and clinical toxicity liability for this class of compounds.

Acknowledgement

We thank Dr. Brian Schultz, Dr. Roman Sakowicz, and Dr. Chin Tay for careful review of this manuscript and insightful comments.

Declaration of conflicting interests

The author is an employee and shareholder of Gilead Sciences, Inc.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Joy Y Feng http://orcid.org/0000-0003-4837-1911

References

1. Elion GB. Nobel lecture: The purine path to chemotherapy. In Vitro Cell Dev Biol 1989; 25: 321–330.
2. Feng JY and Furman PA. Other drug applications. In: M Vaghefi (ed) Nucleoside triphosphates and their analogs: Chemistry, biotechnology, and biological applications. Oxfordshire, UK: Taylor & Francis Group, 2005, pp.343–356.
3. Galmarini CM, Mackey JR and Dumontet C. Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol 2002; 3: 415–424.
4. Clair S, Furman MH, Lubbers PA, et al. Inhibition of cellular z and virally induced deoxyribonucleic acid polymerases by the triphosphate of acyclovir. Antimicrob Agents Chemother 1980; 18: 741–745.
5. De Clercq E. A 40-year journey in search of selective antiviral chemotherapy. Annu Rev Pharmacol Toxicol 2011; 51: 1–24.
6. Brinkman K and Kakuda TN. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy? Curr Opin Infect Dis 2000; 13: 5–11.
7. Johnson AA, Ray AS, Hanes J, et al. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem 2001; 276: 40847–40857.
8. Chen CH and Cheng YC. The role of cytoplasmic deoxycytidine kinase in the mitochondrial effects of the anti-human immunodeficiency virus compound, 2',3'-dideoxycytidine. J Biol Chem 1992; 267: 2856–2859.
9. Chen CH, Vazquez-Padua M and Cheng Y-C. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol Pharmacol 1991; 39: 625–628.
10. Lewis LD, Hamzeh FM and Lietman PS. Ultrastructural changes associated with reduced mitochondrial DNA and impaired mitochondrial function in the presence of 23'-dideoxycytidine. Antimicrob Agents Chemother 1992; 36: 2061–2065.
11. Arnaudo E, Dalakas M, Shanske S, et al. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 1991; 337: 508–510.
12. Johnson AA, Tsai Y, Graves SW, et al. Human mitochondrial DNA polymerase holoenzyme: reconstitution and characterization. Biochemistry 2000; 39: 1702–1708.
13. Institute of Medicine. Review of the fialuridine (FI AU) clinical trials. Washington, DC: The National Academies Press, 1995, p.280.
14. Lewis W, Griniuviene B, Tankersley KO, et al. Depletion of mitochondrial DNA, destruction of mitochondria, and accumulation of lipid droplets result from fialuridine treatment in woodchucks (Marmota monax). Lab Invest 1997; 76: 77–87.
15. McKenzie R, Fried MW, Sallie R, et al. Hepatic failure and lactic acidosis due to fialuridine (FI AU): An investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995; 333: 1099–1105.
16. U.S. Department of Health and Human Services (HHS), Food and Drug Administration (FDA) and Center for
Drug Evaluation and Research (CDER). Guidance for industry: Antiviral product development - Conducting and submitting virology studies to the agency. Rockville, MD, 2006.

17. Brown NA. Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: Nucleoside analogues. Expert Opin Investig Drugs 2009; 18: 709–725.

18. Bristol-Myers Squibb. Bristol-Myers Squibb discontinues development of BMS-986094: An investigational NS5B nucleotide for the treatment of hepatitis C [Press Release]. BusinessWire, 2012.

19. Idenix Pharmaceuticals. Idenix pharmaceuticals provides update on IDX184 and IDX19368 development programs [General Release]. BusinessWire, 2012.

20. Feng JY, Xu Y, Barauskas O, et al. Role of mitochondrial RNA polymerase in the toxicity of nucleotide inhibitors of hepatitis C virus. Antimicrob Agents Chemother 2016; 60: 806–817.

21. Jin Z, Kinkade A, Behera I, et al. Structure-activity relationship analysis of mitochondrial toxicity caused by antiviral ribonucleoside analogs. Antiviral Res 2014; 103: 151–161.

22. Mery B, Guy JB, Vallard A, et al. In vitro cell death determination for drug discovery: A landscape review of real issues. J Cell Death 2017; 10: 1–8.

23. Birkus G, Hitchcock MJM and Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002; 46: 716–723.

24. Richardson FC, Tennant BC, Meyer DJ, et al. An evaluation of the toxicities of 2'-fluorouridine and 2'-fluoro- cytidine-HCl in F344 rats and woodchucks (Marmota monax). Toxicol Pathol 1999; 27: 607–617.

25. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Attachment to guidance on antiviral product development—Conducting and submitting virology studies to the agency - Guidance for submitting HBV resistance data. 2006, pp.100–4.

26. Pereira CV, Moreira AC, Pereira SP, et al. Investigating drug-induced mitochondrial toxicity: a biosensor to increase drug safety? Curr Drug Saf 2009; 4: 34–54.

27. Bari A, Josephson L, Prince AM, et al. Book reviews: Letters to the editor. New Engl J Med 1996; 334: 1135–1138.

28. Pharmasset Inc. Pharmasset announces intent to amend QUANTUM trial [Press Release]. Princeton, NJ: BusinessWire, 2011.

29. Vertex Pharmaceuticals Incorporated. Vertex provides update on ongoing all-oral studies of VX-135 in hepatitis C [Press Release]. Cambridge, MA: BusinessWire, 2013.

30. Lynx MD and McKee EE. 3’-Azoido-3’-deoxythymidine (AZT) is a competitive inhibitor of thymidine phosphorylation in isolated rat heart and liver mitochondria. Biochem Pharmacol 2006; 72: 239–243.

31. Graci JD and Cameron CE. Mechanisms of action of ribavirin against distinct viruses. Rev Med Virol 2006; 16: 37–48.

32. Feng JY, Cheng G, Perry J, et al. Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug. Antimicrob Agents Chemother 2014; 58: 1930–1942.

33. Jin Z, Kinkade A, Behera I, et al. Structure-activity relationship analysis of mitochondrial toxicity caused by antiviral ribonucleoside analogs. Antiviral Res 2017; 143: 1–43.

34. Fenaux M, Lin X, Yokokawa F, et al. Antiviral nucleoside ribonucleosides. PLoS Pathog 2012; 8: e1003030.

35. Arnold JJ, Sharma SD, Feng JY, et al. Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosides. PLoS Pathog 2012; 8: e1003030.

36. Nadanaciva S, Aleo MD, Strock CJ, et al. Toxicity assessment of nonsteroidal anti-inflammatory drugs in isolated mitochondria, rat hepatocytes, and zebrafish show good concordance across chemical classes. Toxicol Appl Pharmacol 2013; 272: 272–280.

37. Hynes J, Nadanaciva S, Swiss R, et al. A high-throughput dual parameter assay for assessing drug-induced mitochondrial dysfunction provides additional predictivity over two established mitochondrial toxicity assays. Toxicol In Vitro 2013; 27: 560–569.

38. Will Y and Dykens J. Mitochondrial toxicity assessment in industry - A decade of technology development and insight. Expert Opin Drug Metab Toxicol 2014; 10: 1061–1067.
46. Business Wire. BioCryst provides update regarding BCX5191 development plan following discussion with FDA [Press Release]. Research Triangle Park, NC: BusinessWire, 2012.

47. Yin Z, Chen YL, Schul W, et al. An adenosine nucleoside inhibitor of dengue virus. Proc Natl Acad Sci USA 2009; 106: 20435–20439.

48. Blomme EA and Will Y. Toxicology strategies for drug discovery: Present and future. Chem Res Toxicol 2016; 29: 1–118.

49. Ong MM, Latchoumycandane C and Boelsterli UA. Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. Toxicol Sci 2007; 97: 205–213.

50. Xu D, Nishimura T, Nishimura S, et al. Fialuridine induces acute liver failure in chimeric TK-NOG mice: A model for detecting hepatic drug toxicity prior to human testing. PLoS Med 2014; 11: 1–9.